Q1 2024 Financial Results

Appendix

25

Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures

(In thousands, except per share amounts)

26 Please note that the figures presented may not sum exactly due to rounding

Alnylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Growth at Constant Currency

Please note that the figures presented may not sum exactly due to rounding

27 Constant Currency = Constant Exchange Rate, or CER

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Alnylam Pharmaceuticals Inc. published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2024 12:58:18 UTC.